Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Melanoma 11Carcinoma, Renal Cell 10Carcinoma, Non-Small-Cell Lung 6Prostatic Neoplasms 4Neoplasm Metastasis 4Myelodysplastic Syndromes 4Lung Neoplasms 4Clear-cell metastatic renal cell carcinoma 4Urinary Bladder Neoplasms 3Urethral Neoplasms 3Leukemia, Myeloid, Acute 3Histiocytoma, Malignant Fibrous 3Carcinoma, Transitional Cell 3Carcinoma, Basal Cell 3Urogenital Neoplasms 2Ureteral Neoplasms 2Thyroid Neoplasms 2Sarcoma 2Penile Neoplasms 2Ovarian Neoplasms 2Nasopharyngeal Carcinoma 2Glioblastoma 2Carcinoma, Merkel Cell 2Carcinoma, Endometrioid 2Brain Neoplasms 2Adenocarcinoma of Lung 2Vulvar Neoplasms 1Uveal Melanoma 1Urachal adenocarcinoma 1Triple Negative Breast Neoplasms 1

Interventions

trastuzumab deruxtecan 1sacituzumab govitecan 1Temozolomide 1Social Determinants of Health 1Methylprednisolone 1Irinotecan 1Cefixime 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Drug-Related Side Effects and Adverse Reactions × CTLA-4 Antigen × 90 days × Clear all
NCT04659343 2026-05-04

TDM for Optimized Outcome in Patients With mRCC.

University of Aarhus

Recruiting
200 enrolled
Genitourinary

Kidney Neoplasms, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡